Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06650488 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Clopidogrel vs. Aspirin for Cardiovascular Risk Reduction in Patients With S. Aureus Bacteremia

Study acronym: Clopido-SNAP 2
StatusRecruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Eligibility criteria expanded, about 4 words
  2. Study sites: 1 to 3
    • Eligibility criteria expanded, about 7 words
    • Secondary endpoints: details revised at 5 of 9 entries
    • Publications: details revised at 3 of 3 entries
  3. Study title expanded, about 1 wordv5
  4. Re-verified, no change to tracked fieldsv4
  5. Study title expanded, about 3 wordsv3
  6. Trial status: Not Yet Recruiting to Recruiting
    • Primary and study completion dates: Jan 2029 to Jan 2030
    • Start date changed from estimate of Jan 7, 2025 to Jan 15, 2026
    • Site details revised
    v2
  7. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is an open-label randomized controlled trial which will enroll patients with S. aureus bacteremia who are already taking aspirin for secondary prevention of cardiovascular events. We will randomize patients to continue their aspirin or change clopidogrel which is also approved for secondary prevention. Unlike aspirin, clopidogrel may have activity against S. aureus. We wish to determine if changing to clopidogrel will improve outcomes in S. aureus bacteremia in people who otherwise would have a reason to be taking it. This study is an approved sub-study of The Staphylococcus aureus Network Adaptive Platform (SNAP) trial (NCT05137119). If positive, this study will support a Phase 3 RCT in people who do not currently have an indication for clopidogrel.
Trial Details
NCT Number NCT06650488
Lead Sponsor Todd C. Lee MD MPH FIDSA
Conditions
(from sponsor)		 Staphylococcus Aureus Endocarditis, Staphylococcus Aureus Septicemia, Staphylococcus Aureus Bloodstream Infection
Enrollment 300 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov